761 Topically-delivered gene suppressing nanocontruct targets IL-17RA for psoriasis

Activated interleukin (IL)-23/Th17 signaling is critical for psoriasis pathogenesis, and systemic IL-17 inhibitors are highly effective therapy. However, most patients have mild to moderate disease and no targeted topical therapeutic option. We developed a topically-delivered gene regulating nanoconstruct, comprised of antisense DNA or siRNA in a dense spherical configuration. These spherical nucleic acids or SNAs penetrate the skin barrier to knock down cutaneous gene targets. We generated anti-human and anti-mouse liposomal DNA SNAs targeting the IL-17A receptor (ILRA) and tested their efficacy in reducing IL17RA and improving markers of psoriasis in human 3D and imiquimod-induced mouse models of psoriasis.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Genetic Disease, Gene Regulation, and Gene Therapy Source Type: research